14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.91 $2.54 Friday, 3rd May 2024 CANF stock ended at $2.09. This is 2.96% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 6.44% from a day low at $2.02 to a day high of $2.15.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
May 06, 2022 $0.97 $0.97 $0.91 $0.91 94 474
May 05, 2022 $0.98 $0.98 $0.94 $0.94 40 735
May 04, 2022 $0.98 $0.98 $0.93 $0.95 230 948
May 03, 2022 $0.97 $0.98 $0.93 $0.96 61 781
May 02, 2022 $1.04 $1.04 $0.92 $0.97 136 558
Apr 29, 2022 $0.95 $1.00 $0.93 $0.93 77 285
Apr 28, 2022 $0.96 $0.99 $0.90 $0.95 221 483
Apr 27, 2022 $0.96 $1.02 $0.94 $0.99 136 362
Apr 26, 2022 $0.98 $1.00 $0.92 $0.93 142 541
Apr 25, 2022 $1.05 $1.05 $0.92 $1.01 386 883
Apr 22, 2022 $0.95 $0.98 $0.94 $0.97 202 966
Apr 21, 2022 $1.07 $1.08 $1.00 $1.00 88 379
Apr 20, 2022 $1.07 $1.09 $1.05 $1.08 103 254
Apr 19, 2022 $1.05 $1.09 $1.05 $1.08 88 196
Apr 18, 2022 $1.17 $1.17 $1.05 $1.05 101 725
Apr 14, 2022 $1.10 $1.13 $1.06 $1.12 181 131
Apr 13, 2022 $1.11 $1.13 $1.06 $1.08 229 994
Apr 12, 2022 $1.12 $1.15 $1.09 $1.10 177 660
Apr 11, 2022 $1.12 $1.17 $1.12 $1.15 126 312
Apr 08, 2022 $1.11 $1.19 $1.08 $1.13 79 068
Apr 07, 2022 $1.18 $1.19 $1.10 $1.14 129 260
Apr 06, 2022 $1.24 $1.24 $1.16 $1.17 197 579
Apr 05, 2022 $1.26 $1.28 $1.20 $1.21 395 440
Apr 04, 2022 $1.17 $1.27 $1.17 $1.22 217 424
Apr 01, 2022 $1.28 $1.28 $1.19 $1.19 342 229
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT